Biotech Oncology

Sector thesis

Biotech oncology is the business of discovering and developing drugs to treat cancer. Companies in this space range from tiny startups testing one experimental molecule to giants like Merck and Bristol Myers Squibb with dozens of approved treatments and billions in annual revenue. The sector is driven by a simple megatrend: cancer rates are rising globally as populations age, and patients (and insurers) are willing to pay premium prices for drugs that extend or improve life. Within oncology, three sub-categories matter most. First, traditional chemotherapy and targeted drugs—older, proven approaches that still dominate revenue. Second, immunotherapy—drugs that train the immune system to attack cancer cells, a major innovation of the past decade. Third, precision medicine—treatments tailored to a patient's specific tumor genetics, often paired with diagnostic tests. These overlap, but they shape how companies compete and where money flows. The biggest risk is binary: most experimental drugs fail. A biotech company might spend a decade and hundreds of millions developing a treatment, only to discover in late-stage trials it doesn't work or causes unacceptable side effects. That's why biotech stocks are volatile. A single trial result can cut a company's value in half. Regulatory approval is also unpredictable—the FDA can reject a drug even if early data looks promising. Finally, pricing pressure is real. Governments and insurers increasingly demand lower drug prices, which squeezes margins. For a retail portfolio, oncology biotech is high-risk, high-reward. Most investors shouldn't buy individual small-cap biotech stocks unless they can afford to lose that money. Instead, watch large-cap pharma companies with diversified oncology pipelines, or biotech-focused ETFs that spread risk across many bets. Pay attention to clinical trial announcements and FDA decisions—these drive short-term moves. The sector rewards patience and diversification, not stock-picking.